- ￥2640
- CUSABIO
- CN
- CSB-PA006163KA01HU
- 2025年07月11日
- ELISA,WB,IHC;WB:1:500-1:2000,IHC:1:50-1:200
- Rabbit
- Human
企业认证
相关产品推荐更多 >
PTBP2抗体PTBP2兔多抗抗体Splicing regulator antibody抗体PTBP2 Antibody, Biotin conjugated抗体
￥880![/抗体/兔多抗抗体3D)] antibody抗体Genome polyprotein Antibody, FITC conjugated抗体](https://img1.dxycdn.com/p/s14/2024/0814/583/4899487679213463281.jpg!wh200)
/抗体/兔多抗抗体3D)] antibody抗体Genome polyprotein Antibody, FITC conjugated抗体
￥880
SNRPE抗体SNRPE兔多抗抗体snrpe antibody抗体SNRPE Antibody, FITC conjugated抗体
￥880
/抗体/兔多抗抗体/抗体ADAM32 Antibody抗体
￥2024
KRT72抗体KRT72兔多抗抗体Type-II keratin Kb35 antibody抗体KRT72 Antibody抗体
￥440
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 询价记录
- 文献和实验
- 技术资料
- 免疫原：
A synthetic peptide of Human CTLA4
- 亚型：
IgG
- 形态：
Liquid
- 保存条件：
Upon receipt, store at -20℃ or -80℃. Avoid repeated freeze.
- 克隆性：
/
- 标记物：
/
- 适应物种：
Human
- 保质期：
6个月
- 抗原来源：
Homo sapiens (Human)
- 目录编号：
P16410
- 级别：
优
- 库存：
200
- 供应商：
武汉华美生物工程有限公司
- 宿主：
Rabbit
- 应用范围：
ELISA,WB,IHC;WB:1:500-1:2000,IHC:1:50-1:200
- 浓度：
>95%,Affinity purification
- 靶点：
CTLA4
- 抗体英文名：
CTLA4 Antibody
- 抗体名：
CTLA4;CD152;Cytotoxic T-lymphocyte protein 4;Cytotoxic T-lymphocyte-associated antigen 4;CTLA-4;CD antigen CD152
- 规格：
100μl
保存缓冲液
Store at -20oC or -80oC. Avoid freeze / thaw cycles. Buffer: PBS with 0.02% sodium azide, 50% glycerol, pH7.3.功能
This gene is a member of the immunoglobulin superfamily and encodes a protein which transmits an inhibitory signal to T cells. The protein contains a V domain, a transmembrane domain, and a cytoplasmic tail. Alternate transcriptional splice variants, encoding different isoforms, have been characterized. The membrane-bound isoform functions as a homodimer interconnected by a disulfide bond, while the soluble isoform functions as a monomer. Mutations in this gene have been associated with insulin-dependent diabetes mellitus, Graves disease, Hashimoto thyroiditis, celiac disease, systemic lupus erythematosus, thyroid-associated orbitopathy, and other autoimmune diseases. [provided by RefSeq, Jul 2008]风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
- 作者
- 内容
- 询问日期
文献和实验Nature 综述导读：FDA 批准第 100 个抗体药物！抗体药物的研究方向在哪里？
仍超过 50 亿美元。 图七 Journal of Biomedical Science (2020) 27:1来自抗体协会 (Antibody Society) 的数据显示，临床管道中也存在类似的大量内卷现象。目前有将近 870 种抗体在临床开发中，但其中大约 36% 的抗体集中在下表二的 10 个靶点中。PD1/PDL1、HER2、CTLA4、EGFR 和 CD20 仍然占据较高的比例。 表二：Nature Reviews Drug Discovery 20, 10 (2021)癌症将继续占据
Receptor for CD80 (B7) & CD86 (BB1), found on activated B cells Constitutive, high abundance, low affinity receptor; opposite signals are mediated by CTLA4 (CD152) Result of T cell antigen stimulation depends on sum of effects of T cell
Aka B7-2 Ligand for CD28 (CD80 also binds CD28), CD152 (CTLA4) Induction of an immune response requires T cells to receive 2 sets of signals from antigen presenting cells. The first is delivered through the T-cell receptor complex
技术资料暂无技术资料 索取技术资料
